THAI BIO LABS
฿500 OFF

Join the THAI BIO LABS Research Digest

Stay up to date with the latest published research and evidence on metabolic research peptides across our catalogue.

Enjoy an additional ฿500 off your first purchase of any metabolic research peptide. No minimum spend.

One email a month. Unsubscribe at any time.

สมัครรับข่าวสารงานวิจัยจาก THAI BIO LABS

Research Digest คือจดหมายข่าวรายเดือนที่รวบรวมงานวิจัยและหลักฐานที่เผยแพร่ล่าสุดเกี่ยวกับเปปไทด์กลุ่มเมตาบอลิกในแคตตาล็อกของเรา

รับส่วนลดเพิ่ม 500 บาท สำหรับการซื้อเปปไทด์สำหรับการวิจัยด้านเมตาบอลิซึมครั้งแรก โดยไม่มียอดซื้อขั้นต่ำ

รับอีเมลเดือนละ 1 ฉบับ ยกเลิกรับข่าวสารได้ทุกเมื่อ

By subscribing, you agree to receive the monthly Research Digest. Unsubscribe at any time.

One-time welcome offer. Bacteriostatic water excluded.
THAI BIO LABS
CART 0 LOT RECORD Batch Records
Menu × Close
Catalogue Batch Records Evidence Library Knowledge Center Calculator Quality Standards Cart (0)

Scientific Evidence Record · Cellular Energy

SS-31 · ELAMIPRETIDE

A scientific record of the published literature, kept separate from THAI BIO LABS lot-level analytical documentation and commercial availability.

Selected sources checked: · Content version2.1 · AI-assisted screening; specialist review pending

Selected evidenceIndication-specific clinical findings
Supply contextResearch supply only
Review statusSpecialist review pending
Reading framework

Scope of this summary

Barth syndrome pharmaceutical evidence · Primary mitochondrial myopathy trials

Review contents

THAI BIO LABS scientific assessment

Evidence in context.

Key takeaways
  • Regulatory evidence is product- and indication-specific. [1]
  • The negative MMPOWER-3 primary results remain visible. [2]

SS-31/elamipretide requires an indication-specific account. The FDA granted accelerated approval to the pharmaceutical product Forzinity for a defined Barth syndrome population, while MMPOWER-3 did not meet its primary efficacy endpoints in primary mitochondrial myopathy. Both belong in the summary. [1][2]

Research overview

What the published record is evaluating.

The approval concerns a regulated elamipretide pharmaceutical product. It does not grant approval to a research vial bearing the SS-31 name or establish formulation equivalence. [1]

Selected studies

Findings and their limits.

On 19 September 2025, the FDA announced accelerated approval for Barth syndrome in patients weighing at least 30 kg. The decision used knee-extensor strength as a measure considered reasonably likely to predict benefit and required a confirmatory trial. This is narrower than a general claim about energy or longevity. [1]

The FDA snapshot describes 12 participants in the randomised crossover trial. The walk and fatigue primary endpoints did not show superiority over placebo; increases in knee-extensor strength were observed during the open-label extension. [3]

MMPOWER-3 randomised 218 people with primary mitochondrial myopathy for 24 weeks. It found no significant improvement over placebo in the six-minute walk test or its primary fatigue score. A different disease setting and a negative trial cannot be replaced by the Barth syndrome approval. [2]

Primary research areas
  • Barth syndrome pharmaceutical evidence
  • Primary mitochondrial myopathy trials

Evidence quality

Strengths and limitations, shown together.

Strengths
  • An official FDA decision and a published randomised phase 3 study provide independently checkable records. [1][2]
Current limitations
  • Accelerated approval includes a requirement to confirm clinical benefit. [1]
  • These sources do not establish performance enhancement or lifespan extension in healthy adults.

Safety & tolerability evidence

Published safety context.

The FDA announcement identifies injection-site reactions and notes serious reactions. Safety information belongs to the studied/approved formulation; a research vial needs its own analytical record and is not supplied for human use. [1]

Scientific outlook

Where the evidence may develop next.

Track the confirmatory Barth syndrome study and prospectively designed indication-specific trials separately from post hoc hypotheses.

Selected references

Selected references from the published record.

These linked sources support the numbered statements above. This is a selected summary, not an exhaustive or independently signed-off systematic review. Sponsor announcements are labelled separately from published studies.

  1. FDA. Forzinity accelerated approval, 19 September 2025. · Regulatory source
  2. Karaa et al. MMPOWER-3. Neurology, 2023. PMID 37268435. · Primary study
  3. FDA. Drug Trials Snapshots: Forzinity — SPIBA-201. · Regulatory source

INTERPRETATION FRAMEWORK

Different records. Different questions.

Three connected layers help interpret the evidence. They answer different questions and cannot substitute for one another.

Narrative Review

What the published scientific record reports, including its scope, findings and limitations.

Evidence Index

A structured reading framework. For metabolic peptides, it also preserves the original dated editorial scores and component breakdowns.

Batch Record

Analytical identity and other lot-specific documentation for a THAI BIO LABS material, when published.

Use the Evidence Index to examine the research interpretation and Batch Records to review documentation for a specific lot.

Research-use boundary

Clinical literature and THAI BIO LABS research materials are not the same record.

Published studies may concern approved medicines, investigational pharmaceutical material or other controlled research preparations. THAI BIO LABS materials are supplied for laboratory research use only and are not represented as medicines or substitutes for regulated pharmaceutical products.

LINE